Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AZURE-2: BJT-778 vs bulevirtide in chronic hepatitis D
2024-517167-23-00Phase 3Authorised
- Sponsor
- Mirum Pharmaceuticals, Inc.
- Start
- Aug 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 10
01
Overview
Phase 3, randomised, open-label trial of brelovitug in Chronic Viral Hepatitis B With Delta-Agent (2 arms), sponsored by Mirum Pharmaceuticals, Inc. Primary endpoint: Composite virologic and biochemical response at primary timepoint. Planned start Aug 2025; status: authorised.
02
Drugs
brelovitug
03
Conditions
Chronic Viral Hepatitis B With Delta-Agent
Beyond the preview
Go deeper on 2024-517167-23-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-517167-23-00.